H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the ...

H.C. Wainwright analyst Amit Dayal lowered the firm’s price target on ClearSign (CLIR) to $2 from $6 and keeps a Buy rating on the shares. The ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.08, a high estimate of ...

Richtech Robotics ( NASDAQ: RR) rallied in late Friday morning trading after H.C. Wainwright initiated coverage on the stock with a Buy rating.

Fintel reports that on April 10, 2025, HC Wainwright & Co. downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of Bionano Genomics (NasdaqCM:BNGO) with a Buy recommendation. Analyst Price Forecast Suggests 2,062.54% Upside As of April ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Research analysts at HC Wainwright upped their Q1 2025 EPS estimates for shares of Nurix Therapeutics in a report released on ...

Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st. HC Wainwright analyst E. Bodnar now expects that the company will post ...